title: Importance of screening logs in clinical trials for severe traumatic brain injury.
abstract: OBJECTIVE
  The primary intent for obtaining screening logs in a randomized clinical trial is to assess selection bias in patient recruitment. This is particularly relevant to focused trials in heterogeneous populations such as traumatic brain injury (TBI) patients. We aimed to investigate the benefits of collecting screening logs in two randomized clinical trials conducted in TBI.
  
  
  METHODS
  Screening logs were collected as part of the conduct of two multicenter trials of neuroprotective agents in TBI: the Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk study (n = 924) and the dexanabinol study (n = 861). Centers were requested to submit monthly information on all patients with TBI admitted to the intensive care unit, including demographics, time of injury and admission, injury severity, and, if not recruited, the reason(s) for exclusion.
  
  
  RESULTS
  In the Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk study, 52 centers submitted admission data on 4166 patients. In the dexanabinol trial, 96 centers submitted data on 7052 patients. On average, only 20% of patients screened for the Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk study and 10% for the dexanabinol trial were enrolled. The main reasons for exclusion were neurological status (29 and 26%, respectively), age (24 and 30%, respectively), and admission outside of the time window (17 and 21%, respectively). Differences in patient characteristics between screened and enrolled patients, with substantial country-specific variation, were observed.
  
  
  CONCLUSIONS
  The collection of screening logs is necessary to report trial results according to the Consolidated Standards of Reporting Trials guidelines and to assess the generalizability of findings. Our experience shows the feasibility of collecting screening logs and illustrates how the potential for selection bias may creep into well-designed randomized clinical trials as a result of factors outside the control of investigators. Consistency and accuracy in screening log completion may further serve as an early indicator of center performance in a trial.
authors.affiliation: Department of Neurosurgery, Erasmus Medical Center, Rotterdam, The Netherlands.
authors.forename: François J A
authors.initials: FJ
authors.lastname: Slieker
authors.forename: Erwin J O
authors.initials: EJ
authors.lastname: Kompanje
authors.forename: Gordon D
authors.initials: GD
authors.lastname: Murray
authors.forename: Juha
authors.initials: J
authors.lastname: Ohman
authors.forename: Nino
authors.initials: N
authors.lastname: Stocchetti
authors.forename: Sir Graham
authors.initials: SG
authors.lastname: Teasdale
authors.forename: Andrew I R
authors.initials: AI
authors.lastname: Maas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001930:Brain Injuries / Q000175:diagnosis* / Q000188:drug therapy; D013759:Dronabinol / Q000031:analogs & derivatives / Q000627:therapeutic use; D005240:Feasibility Studies; D005568:Forms and Records Control; D006801:Humans; D008499:Medical Records; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D018579:Patient Selection; D010879:Piperazines / Q000627:therapeutic use
chemical_list: D018696:Neuroprotective Agents; D010879:Piperazines; C065286:SDZ EAA 494; D013759:Dronabinol; C062018:HU 211